{
    "nctId": "NCT03433560",
    "briefTitle": "An Observational Study to Evaluate the Safety and Efficacy of Pegfilgrastim (Neulasta\u00ae)",
    "officialTitle": "An Observational, Prospective, Open Label, Multicenter Study to Evaluate the Safety and Efficacy of Pegfilgrastim (Neulasta\u00ae) as Secondary Prophylaxis to Decrease the Incidence of Febrile Neutropenia in Korean Female Patients With Breast Cancer.",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer Female, Breast Neoplasm Female",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 1300,
    "primaryOutcomeMeasure": "The incidence of febrile neutropenia after secondary prophylaxis with pegfilgrastim",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* \u2265 19 years old, and \u2264 64 years old, and\n* Female patients with breast cancer receiving chemotherapy recently covered under national health insurance (only chemotherapy regimens in the table below), and\n* Patients with neutropenic events (febrile neutropenia or grade 4 neutropenia) in any previous cycle that did not use G-CSF for the prevention of neutropenia\n\nExclusion Criteria:\n\nPatients with any of the followings are excluded.\n\n* Patients with a history of allergic reactions to E-coli derived proteins, human granulocyte colony-stimulating factors such as pegfilgrastim or filgrastim\n* Uses for off-label indications such as chronic myelogenous leukemia, myelodysplastic syndrome",
    "sex": "FEMALE",
    "minimumAge": "19 Years",
    "stdAges": "ADULT"
}